Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Assets Average (2016 - 2025)

Voyager Therapeutics' Assets Average history spans 11 years, with the latest figure at $270.3 million for Q4 2025.

  • For Q4 2025, Assets Average fell 34.0% year-over-year to $270.3 million; the TTM value through Dec 2025 reached $270.3 million, down 34.0%, while the annual FY2025 figure was $322.7 million, 13.3% down from the prior year.
  • Assets Average for Q4 2025 was $270.3 million at Voyager Therapeutics, down from $305.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $452.9 million in Q2 2024 and bottomed at $170.9 million in Q4 2022.
  • The 5-year median for Assets Average is $287.7 million (2023), against an average of $291.1 million.
  • The largest annual shift saw Assets Average soared 88.96% in 2023 before it crashed 34.0% in 2025.
  • A 5-year view of Assets Average shows it stood at $189.3 million in 2021, then decreased by 9.72% to $170.9 million in 2022, then surged by 88.96% to $323.0 million in 2023, then grew by 26.81% to $409.5 million in 2024, then tumbled by 34.0% to $270.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Assets Average are $270.3 million (Q4 2025), $305.2 million (Q3 2025), and $337.7 million (Q2 2025).